Deal Details

GreenLight Announces $108 Million Private Placement Offering

Healthcare

GreenLight private placement offering

Summary

GreenLight Biosciences Holdings, PBC (“GreenLight”) (NASDAQ:GRNA) recently announced a Private Investment in Public Equity offering of 27,640,301 shares of its common stock at a price of $3.92 per share, generating gross proceeds of approximately $108.4 million, before deducting offering expenses. The financing included participation from new and existing institutional investors, including S2G Ventures, BNP Paribas Ecosystem Restoration Fund, Continental Grain Company, Cormorant Asset Management, the Cummings Foundation, Fall Line Capital, the FTX Foundation, Insud Pharma, Morningside Venture Investments, Rivas Capital, Sigmas Group, SymBiosis and certain directors and executive officers of GreenLight.

Baird served as a joint placement agent on this offering.

About

GreenLight aims to address some of the world’s biggest problems by delivering on the full potential of RNA for human health and agriculture. GreenLight’s RNA platform allows us to research, design, and manufacture for human, animal and plant health. In human health, this includes messenger RNA vaccines and therapeutics. In agriculture, this includes RNA to protect honeybees and a range of crops. GreenLight’s human health product candidates are in the pre-clinical stage, and its product candidates for the agriculture market are in the early stages of development or regulatory review. GreenLight Biosciences Holdings, PBC is headquartered in Medford, Massachusetts.